Latest News
AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development
Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...
Latest News
BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?
The BioMarin Fabry deal gives the US company exclusive worldwide rights, outside Korea, to an early-stage injectable enzyme therapy. BioMarin announced the licence on 29 October 2026 with GC Biopharma and Hanmi Pharm. The candidate is HM15421/GC1134A, also known as...
The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026
For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...
ObesityWeek 2026 Preview: The Data to Watch in Washington
ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...
Extracellular Vesicles in Neurology: Is Translation Outpacing Science?
Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
Weekly News Roundup | 26 October 2026
Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...
Melanoma Vaccine Approval: When Could Intismeran Reach Patients?
Melanoma vaccine approval has not happened yet. No regulator has approved intismeran autogene, and its developers have not announced a filing date. On 22 October 2026, Merck and Moderna released detailed phase 3 data. They said they are engaging with regulatory...
Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
From Regulation to Adoption: What Europe Needs Next for AI in Health
The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...
Clinical Trial Results 23 October 2026
The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Why US Federal Legislation Is the Best Chance to Rein In PBMs
Federal legislation is the best opportunity to compel pharmacy benefit managers (PBMs) to change. Neither a major Federal Trade Commission (FTC) settlement nor reforms at the state level have fixed market distortions. But the upcoming US midterm elections in November...
The Evidence Problem in Cosmetic Actives: Why In-Vitro Data Is Not Enough
As Head of R&D at a Swiss cosmetics laboratory, I read a lot of the evidence behind the cosmetic actives that brands ask us to put in their formulas. The same pattern keeps turning up. A well-cited in-vitro mechanism gets marketed as if it were a proven clinical...
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
Weekly News Roundup | 26 October 2026
Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...
Melanoma Vaccine Approval: When Could Intismeran Reach Patients?
Melanoma vaccine approval has not happened yet. No regulator has approved intismeran autogene, and its developers have not announced a filing date. On 22 October 2026, Merck and Moderna released detailed phase 3 data. They said they are engaging with regulatory...
Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
From Regulation to Adoption: What Europe Needs Next for AI in Health
The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...
Clinical Trial Results 23 October 2026
The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Why US Federal Legislation Is the Best Chance to Rein In PBMs
Federal legislation is the best opportunity to compel pharmacy benefit managers (PBMs) to change. Neither a major Federal Trade Commission (FTC) settlement nor reforms at the state level have fixed market distortions. But the upcoming US midterm elections in November...
The Evidence Problem in Cosmetic Actives: Why In-Vitro Data Is Not Enough
As Head of R&D at a Swiss cosmetics laboratory, I read a lot of the evidence behind the cosmetic actives that brands ask us to put in their formulas. The same pattern keeps turning up. A well-cited in-vitro mechanism gets marketed as if it were a proven clinical...
Featured Articles
Further News
Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal
Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...
RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?
Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and...
Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss
A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...
Who Notices When a Clinical Model Drifts?
Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...
Dostarlimab Rectal Cancer: Will the NHS Offer It Outside Wales?
The NHS has made no UK-wide decision on dostarlimab rectal cancer treatment, as of 20 October 2026. The US Food and Drug Administration (FDA) granted accelerated approval on 19 October 2026. The product is GSK’s Jemperli (dostarlimab). Wales has supported off-label...
When the AI Inside a Medical Device Belongs to Someone Else
Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?
The Roche Hansoh ADC deal gives Roche rights outside Greater China to a portfolio of early antibody-drug conjugates. In return, Roche pays $400 million upfront and $110 million on the first anniversary. Hansoh Pharmaceutical announced the strategic collaboration and...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Function Is the Endpoint: Why Aging Research Should Track Reserve
Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.